Drug Landscape ›
Zoledronic acid IV ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 12
Most-reported reactions
Ankle Fracture — 2 reports (16.67%) Deep Vein Thrombosis — 2 reports (16.67%) Arthralgia — 1 report (8.33%) Body Temperature Increased — 1 report (8.33%) Bone Pain — 1 report (8.33%) Bursitis — 1 report (8.33%) Cardiac Failure — 1 report (8.33%) Cellulitis — 1 report (8.33%) Comminuted Fracture — 1 report (8.33%) Decreased Appetite — 1 report (8.33%)
Source database →
Zoledronic acid IV in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Zoledronic acid IV approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for Zoledronic acid IV in United States?
National Taiwan University Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.